安罗替尼三线及以上治疗晚期肺癌的疗效

Efficacy of anlotinib as third-line and above treatment for advanced lung cancer

目的探讨安罗替尼三线及以上治疗晚期肺癌的疗效和安全性。方法回顾性分析54例接受安罗替尼三线及以上治疗的晚期肺癌患者的临床资料,观察安罗替尼的短期疗效和不良反应。结果安罗替尼三线及以上治疗晚期肺癌的客观缓解率为13.0%,疾病控制率为85.2%,中位无进展生存期(PFS)为4.0个月。非小细胞肺癌患者的PFS优于小细胞肺癌患者(P<0.05),而脑转移与无脑转移和单药治疗与联合治疗患者之间的PFS差异均无统计学意义(P>0.05)。主要不良反应为高血压、食欲减退和手足综合征等,但均可控制。结论安罗替尼三线及以上治疗晚期肺癌具有较好的疗效和安全性。

Objective To investigate the efficacy and safety of anlotinib as third-line and above treatment for advanced lung cancer.Methods The clinical data of 54 patients with advanced lung cancer were treated with anlotinib as third-line and above treatment were analyzed retrospectively.The short-term efficacy and adverse responses of anlotinib were observed.Results The objective remission rate,disease control rate and median progression-free survival(PFS)were 13.0%,85.2%and 4.0 months,respectively,in the patients with advanced lung cancer treated with anlotinib as third-line and above treatment.The PFS was longer in the patients with non-small cell lung cancer than that in those with small cell lung cancer(P<0.05).There was no significant difference in PFS between the patients with brain metastasis and those without brain metastasis,and between the patients with single drug and those with combined treatment(P>0.05).The common adverse responses were hypertension,anorexia and hand-foot syndrome,which could be controlled.Conclusion Anlotinib has good efficacy and safety as third-line and above treatment for advanced lung cancer.